Related Experiment Video

Updated: Aug 17, 2025

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

1.9K

Multikinase Inhibitor Treatment Patterns for Advanced Thyroid Cancer in Japan: An Administrative Claims Database

Chie Masaki1, Kiminori Sugino2, Yoshinori Tanizawa3

  • 1Department of Surgery, Ito Hospital, 4-3-6 Jingu-mae, Shibuya-ku, Tokyo, 150-8308, Japan. c-masaki@ito-hospital.jp.

Drugs - Real World Outcomes
|December 17, 2022
PubMed
Abstract

Insights

Most advanced thyroid cancer patients in Japan receive only one line of multikinase inhibitor (MKI) treatment. Less than half of patients who stop first-line MKI therapy proceed to second-line treatment.

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Health Services Research

Background:

  • Multikinase inhibitors (MKIs) like sorafenib, lenvatinib, and vandetanib are approved for advanced thyroid cancer (TC) in Japan.
  • The real-world sequential treatment patterns of MKIs in Japanese clinical practice remain unclear.

Purpose of the Study:

  • To investigate the sequential treatment patterns of multikinase inhibitors (MKIs) in patients with advanced thyroid cancer (TC) in Japan.
  • To analyze the duration of MKI treatment and the uptake of second-line therapy.

Main Methods:

  • A retrospective observational cohort study utilizing a Japanese administrative claims database from April 2008 to September 2021.
  • Included patients with papillary (PTC), follicular (FTC), medullary (MTC), or anaplastic (ATC) thyroid cancer who received MKI treatment.
  • Kaplan-Meier analysis was used to estimate overall MKI treatment duration.

Main Results:

  • The study included 795 patients: 447 PTC, 86 FTC, 32 MTC, and 230 ATC.
  • First-line MKIs were predominantly lenvatinib for PTC, FTC, and ATC, and vandetanib for MTC.
  • Among patients discontinuing first-line MKI, only 26.3% (PTC), 21.4% (FTC), 50.0% (MTC), and 4.9% (ATC) received second-line treatment.

Conclusions:

  • Advanced thyroid cancer treatment options are limited, with most patients receiving only first-line MKI therapy.
  • Sequential treatment beyond the first line is infrequent, with less than 50% of patients progressing to second-line therapy after discontinuing first-line treatment.

More Related Videos

Spontaneous Murine Model of Anaplastic Thyroid Cancer05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

1.7K
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

593

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
239